A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

NCT01703572 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Lymphoid Malignancies

Interventions

DRUG: OMP-52M51

Sponsor

OncoMed Pharmaceuticals, Inc.